Bausch Health Companies Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Bausch Health Companies Inc. (BHC) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $450.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-07-30
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $450.00M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $674.00M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $234.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $478.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $450.00M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $674.00M 10-Q · filed 2026-04-30 |
| 2025-09-30 | $234.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $478.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $732.00M 10-Q · filed 2025-05-01 |
| 2024-09-30 | $261.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $528.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $801.00M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $281.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $483.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $756.00M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $274.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $565.00M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $870.00M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $320.00M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $660.00M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.02B 10-Q · filed 2021-05-04 |
| 2020-09-30 | $380.00M 10-Q · filed 2020-11-03 |
| 2020-06-30 | $769.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.19B 10-Q · filed 2020-05-07 |
| 2019-09-30 | $444.00M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $924.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $1.41B 10-Q · filed 2019-05-06 |
| 2018-09-30 | $508.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.36B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $2.17B 10-Q · filed 2018-05-08 |
| 2017-09-30 | $584.00M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $1.22B 10-Q · filed 2017-08-08 |
| 2017-03-31 | $1.82B 10-Q · filed 2017-05-09 |
| 2016-09-30 | $2.67B 10-Q · filed 2016-11-09 |
| 2016-06-30 | $2.67B 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.68B 10-Q · filed 2016-06-07 |
| 2015-09-30 | $2.21B 10-Q · filed 2015-10-26 |
| 2015-06-30 | $2.22B 10-Q · filed 2015-07-28 |
| 2015-03-31 | $1.47B 10-Q · filed 2015-04-30 |
| 2014-09-30 | $1.42B 10-Q · filed 2014-10-24 |
| 2014-06-30 | $1.41B 10-Q · filed 2014-08-01 |
| 2014-03-31 | $1.45B 10-Q · filed 2014-05-09 |
| 2013-09-30 | $1.24B 10-Q · filed 2013-11-01 |
| 2013-06-30 | $1.20B 10-Q · filed 2013-08-07 |
| 2013-03-31 | $1.16B 10-Q · filed 2013-05-03 |
| 2012-09-30 | $849.23M 10-Q · filed 2012-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |